World J Oncol

World Journal of Oncology, ISSN 1920-4531 print, 1920-454X online, Open Access

Article copyright, the authors; Journal compilation copyright, World J Oncol and Elmer Press Inc

Journal website https://www.wjon.org

Original Article

Volume 13, Number 2, April 2022, pages 59-68

The Relationship Between Parametrial Involvement and Parametrial Tissue Removed in Radical Surgery in Early-Stage Cervical Cancer

**Table 1.** Clinical and Histopathological Risk Factors of Patients
	Parametrium-negative (n = 244)	Parametrium-positive (n = 48)	P value
*P < 0.05. SD: standard deviation; BMI: body mass index; PMB: postmenopausal bleeding; HPV: human papillomavirus; OC: oral contraceptive drug; IUD: intrauterine device; SCC: squamous cell cancer.
Age (year), mean ± SD	49.9 ± 11.1	54.6 ± 12.8	0.010*
Gravida, median (min - max)	3 (0 - 9)	3 (0 - 10)	0.274
Parity, median (min - max)	2 (0 - 7)	2.5 (0 - 9)	0.290
BMI, median (min - max)	23.2 (17.3 - 39)	23.8 (18.5 - 37.1)	0.494
CA-125, median (min - max)	16.5 (2.8 - 142)	14 (0.6 - 79.5)	0.453
Smoke, pack/year	12 (0 - 40)	13 (0 - 32)	0.775
Complaint
Asymptomatic	10 (4%)	0	0.093
Postcoital bleeding	94 (38.5%)	16 (33.3%)
Vaginal discharge	70 (28.6%)	11 (22.9%)
PMB	48 (19.7%)	12 (25%)
Pelvic pain	22 (9%)	9 (18.7%)
HPV status
Known	22 (9%)	6 (12.5%)	0.630
Unknown	222 (91%)	42 (87.5%)
Contraception
Not	162 (66.4%)	36 (75%)	0.447
OC	28 (11.5%)	6 (12.5%)
IUD	40 (16.4%)	4 (8.3%)
Condom	14 (5.7%)	2 (4.1%)
Educational status
Literate	86 (35.2%)	6 (12.5%)	0.002*
Not literate	158 (64.7%)	42 (87.5%)
Histology
SCC	166 (68%)	34 (70.8%)	0.846
Adenocarcinoma	70 (28.7%)	12 (25%)
Others	8 (3.3%)	2 (4.1%)
Stage
Ia2	8 (3.3%)	0	NA
Ib1	62 (25.4%)	8 (16.7%)
Ib2	94 (38.5%)	4 (8.3%)
Ib3	34 (13.9%)	12 (25%)
IIa1	18 (7.4%)	10 (20.8%)
IIa2	16 (6.6%)	2 (4.2%)
IIIc1p	12 (4.9%)	10 (20.8%)
IIIc2p	0	2 (4.2%)
Primary treatment
Surgery	68 (27.9%)	6 (12.5%)	0.001*
Surgery + adjuvant radiotherapy	74 (30.3%)	4 (8.3%)
Surgery + adjuvant chemoradiotherapy	102 (41.8%)	38 (79.2%)

Table 1. Clinical and Histopathological Risk Factors of Patients

Parametrium-negative (n = 244)

Parametrium-positive (n = 48)

P value

*P < 0.05. SD: standard deviation; BMI: body mass index; PMB: postmenopausal bleeding; HPV: human papillomavirus; OC: oral contraceptive drug; IUD: intrauterine device; SCC: squamous cell cancer.

Age (year), mean ± SD

49.9 ± 11.1

54.6 ± 12.8

0.010*

Gravida, median (min - max)

3 (0 - 9)

3 (0 - 10)

0.274

Parity, median (min - max)

2 (0 - 7)

2.5 (0 - 9)

0.290

BMI, median (min - max)

23.2 (17.3 - 39)

23.8 (18.5 - 37.1)

0.494

CA-125, median (min - max)

16.5 (2.8 - 142)

14 (0.6 - 79.5)

0.453

Smoke, pack/year

12 (0 - 40)

13 (0 - 32)

0.775

Complaint

Asymptomatic

10 (4%)

0.093

Postcoital bleeding

94 (38.5%)

16 (33.3%)

Vaginal discharge

70 (28.6%)

11 (22.9%)

PMB

48 (19.7%)

12 (25%)

Pelvic pain

22 (9%)

9 (18.7%)

HPV status

Known

22 (9%)

6 (12.5%)

0.630

Unknown

222 (91%)

42 (87.5%)

Contraception

Not

162 (66.4%)

36 (75%)

0.447

28 (11.5%)

6 (12.5%)

IUD

40 (16.4%)

4 (8.3%)

Condom

14 (5.7%)

2 (4.1%)

Educational status

Literate

86 (35.2%)

6 (12.5%)

0.002*

Not literate

158 (64.7%)

42 (87.5%)

Histology

SCC

166 (68%)

34 (70.8%)

0.846

Adenocarcinoma

70 (28.7%)

12 (25%)

Others

8 (3.3%)

2 (4.1%)

Stage

Ia2

8 (3.3%)

Ib1

62 (25.4%)

8 (16.7%)

Ib2

94 (38.5%)

4 (8.3%)

Ib3

34 (13.9%)

12 (25%)

IIa1

18 (7.4%)

10 (20.8%)

IIa2

16 (6.6%)

2 (4.2%)

IIIc1p

12 (4.9%)

10 (20.8%)

IIIc2p

2 (4.2%)

Primary treatment

Surgery

68 (27.9%)

6 (12.5%)

0.001*

Surgery + adjuvant radiotherapy

74 (30.3%)

4 (8.3%)

Surgery + adjuvant chemoradiotherapy

102 (41.8%)

38 (79.2%)

**Table 2.** Histopathologic Features and Survival Results of the Patients^a
	Parametrial invasion absent (n = 244)	Parametrial invasion present (n = 48)	P value
*P < 0.05. LVSI: lymphovascular space invasion. ^aFollow-up time: 131.2 (0.57 - 268.2) months.
Left parametrium length (cm)	3 (1.5 - 7)	3 (1.4 - 7)	0.262
Left parametrial volume (cm³)	6 (0.48 - 34)	7.5 (1.35 - 24)	0.468
Right parametrium length (cm)	3 (1.5 - 8)	3 (1.5 - 5.5)	0.061
Right parametrial volume (cm³)	7.2 (0.52 - 32)	5.55 (1.37 - 22.1)	0.391
Tumor diameter (cm)	2.05 (0 - 5.3)	2.2 (0.6 - 4.6)	0.074
Tumor diameter subgroup
≤ 2cm	81 (91%)	8 (9%)	0.023*
> 2cm	163 (80.3%)	40 (19.7%)
LVSI
Yes	112 (45.9%)	32 (66.6%)	0.009*
No	132 (54.1%)	16 (33.3%)
Deep stromal invasion
Yes	60 (24.6%)	26 (54.2%)	0.0001*
No	184 (75.4%)	22 (45.8%)
Surgical margin
Yes	1 (0.4%)	8 (16.7%)	0.0001*
No	243 (99.6%)	40 (83.3%)
Lymph node involvement
Yes	24 (9.8%)	18 (37.5%)	0.0001*
No	220 (90.2%)	30 (72.5%)
Recurrence
Yes	68 (27.9%)	32 (66.6%)	0.0001*
No	176 (72.1%)	16 (33.3%)
Death
Yes	40 (16.4%)	28 (58.3%)	0.0001*
No	204 (83.6%)	20 (41.7%)
Follow-up, month	131.2 (0.57 - 268.2)

Table 2. Histopathologic Features and Survival Results of the Patients^a

Parametrial invasion absent (n = 244)

Parametrial invasion present (n = 48)

P value

*P < 0.05. LVSI: lymphovascular space invasion. ^aFollow-up time: 131.2 (0.57 - 268.2) months.

Left parametrium length (cm)

3 (1.5 - 7)

3 (1.4 - 7)

0.262

Left parametrial volume (cm³)

6 (0.48 - 34)

7.5 (1.35 - 24)

0.468

Right parametrium length (cm)

3 (1.5 - 8)

3 (1.5 - 5.5)

0.061

Right parametrial volume (cm³)

7.2 (0.52 - 32)

5.55 (1.37 - 22.1)

0.391

Tumor diameter (cm)

2.05 (0 - 5.3)

2.2 (0.6 - 4.6)

0.074

Tumor diameter subgroup

≤ 2cm

81 (91%)

8 (9%)

0.023*

> 2cm

163 (80.3%)

40 (19.7%)

LVSI

Yes

112 (45.9%)

32 (66.6%)

0.009*

132 (54.1%)

16 (33.3%)

Deep stromal invasion

Yes

60 (24.6%)

26 (54.2%)

0.0001*

184 (75.4%)

22 (45.8%)

Surgical margin

Yes

1 (0.4%)

8 (16.7%)

0.0001*

243 (99.6%)

40 (83.3%)

Lymph node involvement

Yes

24 (9.8%)

18 (37.5%)

0.0001*

220 (90.2%)

30 (72.5%)

Recurrence

Yes

68 (27.9%)

32 (66.6%)

0.0001*

176 (72.1%)

16 (33.3%)

Death

Yes

40 (16.4%)

28 (58.3%)

0.0001*

204 (83.6%)

20 (41.7%)

Follow-up, month

131.2 (0.57 - 268.2)